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Conclusions: Baseline post-surgery, pre-radiotherapy cosmesis
is an important determinant of overall cosmesis at 2 years after
radiotherapy. An important component of breast induration and
shrinkage is actually due to surgery rather than radiotherapy. Lar-
ger breast volume, baseline surgical cosmesis, post-operative
infection and smoking influence late radiotherapy toxicity. Modi-
fication of preventable risk factors such as post-operative infec-
tion and smoking may limit the development of late toxicity.
doi:10.1016/j.ejcsup.2010.06.050
O-50 TARGIT (TARGETED INTRA-OPERATIVE RADIOTHERAPY
FOR EARLY STAGE BREAST CANCER): RESULTS FROM THE TAR-
GIT A RANDOMIZED CONTROLLED TRIAL
Michael Bauma, Jayant S. Vaidya a, Jeffrey S. Tobias a, Mohammed
Keshtgar a, Norman R. Williams a, Frederik Wenz b, Max Bulsara c,
Christobel Saunders d, David Joseph d, on behalf of the TARGIT
Trialists’ Group. aUCL, London, UK. bUniversita¨tsmedizin Mannheim,
Germany. cUniversity of Notre Dame, Fremantle, Australia. d Sir
Charles Gairdner Hospital, Perth, Australia
Background: After breast conserving surgery, 90% of recurrent
cancer occurs within the index quadrant. Hence, restricting radi-
ation therapy to the immediate area around the tumour bed after
removal of the primary tumour may be adequate (Vaidya JS et al.
Br J Cancer 1996;74:820–4).
Materials and methods: Using the technique of partial breast
irradiation developed at UCL (Vaidya JS, Baum M, Tobias JS,
et al. Ann Oncol 2001;12:1075–80) we launched the international
TARGIT A randomized controlled trial in March 2000 comparing
the policies of TARGIT versus standard whole breast external
beam radiotherapy (EBRT) after breast conserving surgery with
local recurrence as the main outcome measure (www.thelan-
cet.com/protocol-reviews/99PRT-47). Accrual from 28 interna-
tional centers reached 2232 in April 2010, with 80% power to
detect a difference in relapse rate of 2.5% (the non-inferiority
margin).
Results: Patient demographic and tumour characteristics are as
follows: mean age 63 years (IQR 57–69), mean tumour size 12 mm
(IQR 9–18 mm), N stage 17% +ve. We intend to present the
unblinded data with an analysis of safety and efficacy.
Conclusions: If this analysis shows non-inferiority, then a clin-
ically significant difference in early local recurrence between
TARGIT and EBRT remains unlikely, making single session partial
breast irradiation with TARGITa plausible new standard of care in
the near future.
doi:10.1016/j.ejcsup.2010.06.051
O-51 CLINICAL OUTCOME OF PATIENTS MANAGED IN A DEDI-
CATED PRIMARY BREAST CANCER CLINIC FOR OLDER WOMEN
(THE CLINIC)
K.L. Cheung a, B.M. Syed a, S.J. Johnston a, L. Winterbottomb, H.
Kennedy b, D.A.L. Morgan c. aDivision of Breast Surgery, University of
Nottingham, Nottingham, UK. bNottingham Breast Institute,
Nottingham, UK. cDepartment of Oncology, Nottingham University
Hospitals, Nottingham, UK
Background: The Clinic was established in 1973. Over the last
decade, it has evolved into a combined surgical/oncology facility
supported by dedicated breast care nurses. Also, surgery, with
integral axillary staging, and adjuvant radiotherapy (RT) and sys-
temic therapy have become standard for most patients though
non-operative treatments (e.g. primary endocrine therapy (PET))
are used in others based on multi-disciplinary assessment in
the Clinic. This study aimed to compare the clinical outcome
across these periods.
Methods: Over 36 years (1973–2009), 1708 women P70 years
with early operable primary breast cancer were managed in the
Clinic according to a single set of clinical guidelines at any time
point. Analysis was carried out based on retrospective review
and continued update of patient records.
Results: As at 50-month median follow-up (maximum = 261):
1973–1999 2000–2009
N 917 791
Treatment N (%) N (%)
Surgery 392 (42.7) 446 (56.4)
PET 510 (55.6) 324 (41.0)
Primary RT 9 (1.0) 12 (1.5)
No treatment 6 (0.7) 9 (1.1)
Adjuvant endocrine
therapya
124 (31.7) 247 (55.5)
Adjuvant RTa 15 (6.3) 155 (38.4)
Outcome (% per annum) p-value
Local recurrencea 2.2 0.5 <0.000
Regional recurrencea 1.8 0.4 <0.000
Contralateral cancer 0.7 0.4 0.091
Metastasis 2.9 1.9 <0.002
5-year breast cancer
specific survival
80% 90% <0.000
5-year overall survival 56% 68% <0.000
a Surgery group only.
Conclusion: In this recent decade, while surgery became the
predominant treatment, a significant proportion of patients
(40%) had non-operative therapies, selection of which was
based on assessment in the Clinic. This management approach
appears to produce excellent clinical outcome, which is signifi-
cantly better than earlier period.
doi:10.1016/j.ejcsup.2010.06.052
O-52 EAST OF ENGLAND BREAST CANCER SURVIVAL CLOSE TO
BEST IN EUROPE
G.C. Wishart a,c, C. Caldas a,c, C.H. Brownb, D.C.
Greenberg b. aCambridge Breast Unit, UK. bEastern Cancer Regis-
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